Economic Evaluation of Immune Tolerance Induction in Children With Severe Hemophilia A and High-Responding Inhibitors: A Cost-Effectiveness Analysis of Prophylaxis With Emicizumab-Reference-Cited by-同舟云学术

Economic Evaluation of Immune Tolerance Induction in Children With Severe Hemophilia A and High-Responding Inhibitors: A Cost-Effectiveness Analysis of Prophylaxis With Emicizumab

Published:2023-03 Issue: Volume:34 Page:31-39
ISSN:2212-1099
Container-title:Value in Health Regional Issues
language:en
Short-container-title:Value in Health Regional Issues

Author:

Camelo Ricardo Mesquita,Barbosa Mariana Michel,Araújo Maiara Silva,Muniz Roberto Lúcio,Guerra Augusto Afonso,Godman Brian,Rezende Suely Meireles,Acurcio Francisco de Assis,Martin Antony P.,Alvares-Teodoro Juliana

Publisher

Elsevier BV

Subject

Health Policy,Pharmacology, Toxicology and Pharmaceutics (miscellaneous),Economics, Econometrics and Finance (miscellaneous)

Reference44 articles.

1. Hemophilia A (factor VIII deficiency);Seaman;Hematol Oncol Clin North Am,2021

2. Srivastava A, Santagostino E, Dougall A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(suppl 6):1-158.

3. The importance of inhibitor eradication in clinically complicated hemophilia A patients;Oldenburg;Expert Rev Hematol,2018

4. Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients;Ljung;Eur J Haematol,2019

5. on the behalf of the HEMFIL Study Group. Inhibitor incidence in haemophilia A under exclusive use of a third-generation recombinant factor VIII concentrate: results of the HEMFIL Cohort Study;Jardim;Br J Haematol,2019

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Budget impact and cost-utility analysis of prophylactic emicizumab versus on-demand bypassing agents for adolescent severe haemophilia A patients with inhibitors in India;Heliyon;2024-03

2. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU;Blood Advances;2024-01-12

3. Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes;Research and Practice in Thrombosis and Haemostasis;2023-05